Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03787602
Title KRT-232 With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kartos Therapeutics, Inc.
Indications

Merkel cell carcinoma

Therapies

Avelumab + KRT-232

KRT-232

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU

Additional content available in CKB BOOST